This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-2. (Cancelled)

3. (Previously Presented) A compound according to claim 6, in which

A or B in each case independently of one another represent hydrogen, tetrazolyl or the group $-N(CH_3)_2$, -NH-(CO)-pyrrolidinyl, -NH-(CO)-pentyl, -NH-(CO)-hexyl, -NH-(CO)-hexyl-NH_2, -NH-(CO)-C_3H_7, -NH-(CO)-CH_2-phenyl, -NH-(CO)-CH_2-NH_2, -NH-(CO)-C_2H_4-NH_2, -NH-(CO)-$CH(NH_2)$-CH_3, -NH-(CO)-$CH(NH_2)$-hydroxyphenyl, -NH-(CO)-$CH(NH_2)$-CH_2-phenyl, -NH-(CO)-$CH(NH_2)$-CH_2-hydroxyphenyl, -NH-(CO)-CH(NH-(CO)-CH_3)-CH_2-phenyl, -NH-(CO)-CH_2-NH-(CO)-CH_3, -NH-(CO)-$N(C_2H_5)(C_2H_4$-piperidinyl), -NH-(CO)-$N(CH_3)(C_2H_4$-piperidinyl), -NH-(CO)-CH_2-$NH(CH_3)$, -CH_2-$N(CH_3)_2$, -NH-(CO)NH-CH_2-COOH , hydantoinyl, -CH_2-COOH

wherein pyrrolidinyl can optionally be substituted with hydroxy or the group –NH_2, –$N(CH_3)_2$ or -NH-(CO)-CH_3,

and wherein hydantoinyl can be substituted with -CH_3, -CH_2-COOH, or –(CO)-thiazolidinonyl,

X represents or the group –NH-,

R^1 represents halogen and

R^2 represents hydrogen or the group -NH-(CO)-phenyl

or -C_2H_4-, -C_3H_6- both can optionally be substituted in one or more places, the same way or differently, with cyano, hydroxy, phenyl, naphthyl, imidazolyl, thiazolyl, pyridyl, 2-oxazolinyl, piperidinyl, –NH_2, -NH-CH_2-thienyl, -NH-pyridinyl-NO_2, -NH-thiazolyl, -SO_2-thienyl, -SO_2-NH_2, -SO_2-CH_3, -SO_2-C_3H_7, pyrrolidinonyl substituted with -COOH, –NH-(CO)-NH-thienyl, –NH-(CO)-NH-phenyl, -NH-(CO)-NH- C_2H_5, -NH-(CO)-$C(CH_3)_3$, -NH-(CO)-S-C_2H_5, -NH-(CS)-NH- C_2H_5, -NH-(CO)-C_2H_5, -NH-(CO)-thienyl, -(CO)-NH-NH_2, -(CO)-NH-CH_2-

(CO)-NH_2, -(CO)-NH-C_2H_5, -COOH, wherein phenyl or imidazolyl, thiazolyl can optionally be substituted in one or more places, the same way or differently, with hydroxy, -CH_3, -NH-(CO)-CH_2-NH_2, -$COOC_2H_5$, -$COOC(CH_3)_3$,


,

,

,

,

,

,

,

,

or

,

or a diastereomer, enantiomer or pharmaceutically acceptable salt thereof.

4. (Previously Presented) A compound according to claim 6, in which A or B in each case independently of one another represent hydrogen or the group -NH-

(CO)-pyrrolidinyl, -NH-(CO)-piperidinyl, -NH-(CO)-morpholinyl, -NH-(CO)-hexyl-NH2, -NH-(CO)-CH(NH2)- hydroxyphenyl, -NH-(CO)-CH(NH2)-CH2-hydroxyphenyl, hydantoin optionally substituted with –CH3,

X represents or the group –NH-,

R^1 represents halogen and

R^2 represents hydrogen, $-C_2H_4$-imidazolyl or $-C_3H_7$ which can optionally be substituted in one or more places, the same way or differently with the group -NH-CH_2-thienyl, -NH-(CO)-C_2H_5, -NH-(CO)-$C(CH_3)_3$,


,

,

,

,

,

,

,

,

or

,

or a diastereomer, enantiomer or pharmaceutically acceptable salt thereof.

5. (Currently Amended) A compound ~~according to claim 4~~, which is
N-[3-[[5-bromo-4-[[3-[[[1-(trifluoromethyl)cyclobutyl]carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,
N-[3-[[5-bromo-4-[[3-[[1-oxo-3-(phenylsulfonyl)propyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,
N-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,
N-[3-[[4-[[3-[[(1-aminocyclopentyl)carbonyl]amino]propyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,
N-[3-[[4-[[3-[[(1-aminocyclobutyl)carbonyl]amino]propyl]amino]-5-iodo-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,
N^1-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-1,1-cyclopentanedicarboxamide,
(4R)-*N*-[3-[[5-bromo-2-[[3-(2,5-dioxo-1-imidazolidinyl)phenyl]amino]-4-pyrimidinyl]amino]propyl]-2-oxo-4-thiazolidinecarboxamide,
(4R)-N-[3-[[5-bromo-2-[[3-(3-methyl-2,5-dioxo-1-imidazolidinyl)phenyl]amino]-4-pyrimidinyl]amino]propyl]-2-oxo-4-thiazolidinecarboxamide,
3-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-2,4-imidazolidinedione,
3-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-1-methyl-2,4-imidazolidinedione,
N'-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-N-ethyl-N-[2-(1-piperidinyl)ethyl]-urea,
N-[3-[[5-bromo-4-[[3-[(2,2-dimethyl-1-oxopropyl)amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,
N-[3-[[2-[[3-[[(2S)-2-amino-3-(4-hydroxyphenyl)-1-oxopropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,

N-[3-[[2-[[3-[[(1-aminocyclohexyl)carbonyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,

N-[3-[[2-[[3-[[(2S)-2-amino-2-phenylacetyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,

N-[3-[[2-[[3-[[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-5-oxo-2-pyrrolidinecarboxamide,

N-[3-[[2-[[3-[[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,

N^1-[3-[[5-bromo-2-[[3-[[(2S)-2-pyrrolidinylcarbonyl]amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]- 1,1-cyclopropanedicarboxamide,

N-[3-[[5-bromo-2-[[3-(2,5-dioxo-1-imidazolidinyl)phenyl]amino]-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,

N-(3-((5-bromo-4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-4-morpholinecarboxamide,

N-(3-((5-bromo-4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-1-pyrrolidinecarboxamide,

N-(3-((5-bromo-4-((3-((2-thienylcarbonyl)amino)propyl)amino)-2-pyrimidinyl)amino)phenyl)-1-pyrrolidinecarboxamide,

N1-(3-((5-bromo-2-((3-((1-pyrrolidinylcarbonyl)amino)phenyl)amino)-4-pyrimidinyl)-amino)propyl)-1,1-cyclopropanedicarboxamide,

N-(3-((5-bromo-4-((3-((1-oxopropyl)amino)propyl)amino)-2-pyrimidinyl)amino)phenyl)-1-pyrrolidinecarboxamide,

N-(3-((5-iodo-4-((3-((2-thienylcarbonyl)amino)propyl)amino)-2-pyrimidinyl)amino)phenyl)-1-pyrrolidinecarboxamide,

N-[3-[[5-bromo-4-[[3-[[[(2S)-5-oxo-2-pyrrolidinyl]carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,

N-[3-[[5-bromo-4-[[3-[[[(2S)-4-oxo-2-azetidinyl]carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,

(4R)-N-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-2-oxo-4-thiazolidinecarboxamide or

N-[3-[[4-[[3-[[(1-aminocyclobutyl)carbonyl]amino]propyl]amino]-5-bromo-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,
or a pharmaceutically acceptable salt thereof.

6. (Currently Amended) A compound of formula (I)



(I)

in which

A or B in each case independently of one another represent hydrogen or the group $-NO_2$, $-NH_2$, $-NR^3R^4$, $-N(C_{1-6}\text{-hydroxyalkyl})_2$, $-NH(CO)-R^5$, $-NHCOOR^6$, $-NR^7-(CO)-NR^8R^9$, $-NR^7-(CS)-NR^8R^9$, $-CO-NR^8R^9$, $-SO_2-CH_3$, 4-bromo-1-methyl-1*H*-pyrazolo-3yl or C_{1-6}-alkyl optionally substituted in one or more places, the same way or differently with cyano, halogen, hydroxy or the group $-NH_2$, –NH-(CO)-R^5, $-SO_2-NHR^3$, $-COOR^5$, $-CONR^8R^9$, $-O-(CO)-R^5$, $-O-(CO)-C_{1-6}$-alkyl-R^5,

X represents an oxygen atom or the group –NH-,

R^1 represents ~~hydrogen,~~ halogen, ~~hydroxymethyl or the group –COOH, –COO iso-propyl, NO_2, –NH-(CO)-$(CH_2)_2$-COOH or –NH-(CO)-$(CH_2)_2$-COO-C_{1-6}-alkyl,~~

R^2 represents C_{1-6}-alkyl optionally substituted in one or more places, the same way or differently, with hydroxy, imidazolyl or the group $-NH_2$, –NH-(CO)O-CH_2-phenyl, -NH-(CO)H, -NH-(CO)-phenyl, -NH-(CO)-CH_2-O-phenyl, -NH-(CO)-CH_2-phenyl, -NH-(CO)-$CH(NH_2)CH_2$-phenyl, -NH-(CO)-CH_2-$CH(CH_3)$-phenyl, -NH-(CO)-CH(NH2)-$(CH2)_2$-COOH,



wherein phenyl can optionally be substituted in one or more places, the same or differently with halogen, C_{1-6}-alkyl or –(CO)-C(CH_2)-C_2H_5, ~~or represents C_3-alkinyl,~~

R^3 or R^4 in each case independently of one another represent hydrogen or C_{1-6}-alkyl optionally substituted in one or more places, the same way or differently, with hydroxy, phenyl or hydroxyphenyl,

or

R^3 and R^4 together form a C_{3-6}-heterocycloalkylring containing at least one nitrogen atom and optionally can be interrupted by one or more oxygen and/or sulfur atoms and/or can be interrupted by one or more –(CO)- groups in the ring and/or optionally can contain one or more possible double bonds in the ring, wherein the C_{3-6}-heterocycloalkylring can optionally be substituted with C_{1-6}-alkyl, C_{1-6}-alkyl-COOH or C_{1-6}-alkyl-NH2,

R^5 represents C_{1-6}-alkyl, C_{2-6}-alkenyl, C_{3-6}-cycloalkyl or phenyl each can optionally be substituted in one or more places, the same way or differently, with halogen, hydroxy, phenyl or with the group –NH_2, -NH(CO)-O-C_{1-6}-alkyl, wherein phenyl can optionally be substituted in one or more places, the same way or differently, with halogen, hydroxy or C_{1-6}-alkyl,

R^6 represents C_{1-6}-alkyl, C_{2-6}-alkenyl or phenyl,

R^7 represents hydrogen or C_{1-6}-alkyl and

R^8 or R^9 in each case independently of one another represent hydrogen, C_{1-6}-alkyl, C_{2-6}-alkenyl, C_{3-6}-cycloalkyl, aryl or phenyl, wherein aryl or phenyl can optionally be substituted in one or more places, the same way or differently, with hydroxy or the group $-NO_2$ or $-N(C_{1-6}\text{-alkyl})_2$

or

R^8 and R^9 together form a C_{3-6}-heterocycloalkylring containing at least one nitrogen atom and optionally can be interrupted by one or more oxygen and/or sulfur atoms and/or can be interrupted by one or more –(CO)- groups in the ring and/or optionally can contain one or more possible double bonds in the ring, wherein the C_{3-6}-heterocycloalkylring can optionally be substituted with the group $-NH_2$,

~~wherein when A and B represent hydrogen, X represents –NH- and R^2 represents C_{1-6}-alkyl,~~

~~then R^1 represents –NH-(CO)-CH(NH_2)-(CH_2)$_2$-COOH or –NH-(CO)-CH(NH2)-(CH_2)$_2$-$COOC_2H_5$;~~

~~wherein when R^1 represents –COO-iso-propyl,~~

~~then X represents –NH- and R^2 represents C3-alkinyl and A or B independently of one another represent the group $-NO_2$ or –NH-(CO)-CF_3, and~~

wherein when ~~R^1 represents halogen,~~ X represents –NH-, B represents hydrogen and R^2 represents C_{1-6}-alkyl substituted with $-NH_2$,

then A represents –NH-(CO)-C_6-cycloalkyl-NH_2,

or a diastereomer, enantiomer or pharmaceutically acceptable salt thereof.

7. (Currently Amended) A compound according to claim 6, in which

A or B in each case independently of one another represent hydrogen or the group -NH-C_2H_4-OH, -NH-CH_2-hydroxyphenyl, -NH-(CO)-pyrrolidinyl, -NH-(CO)-CH(NH_2)-CH_2-phenyl, -NH-(CO)-pentyl-NH_2, -NH-(CO)-hexyl-NH_2, -NH-(CO)-CH_2-NH_2, -NH-(CO)-CH(NH_2)-hydroxyphenyl, -NH-(CO)-CH_2-hydroxyphenyl, -NH-(CO)-CH_2-methylphenyl, -NH-(CO)-C_2H_4-dihydroxyphenyl, -NH-(CO)-CH(OH)-phenyl, -NH-(CO)-CH(NH_2)-CH_2(OH), -NH-(CO)-$C(CH_3)_2NH_2$, -NH-

(CO)-NH(C_2H_5), -CH_2OH, -(CO)-NH-cyclopropyl, -(CO)-NH-$CH(CH_3)_2$,
wherein pyrrolidinyl can optionally be substituted with hydroxy or the group –NH_2,

X represents an oxygen atom or the group –NH-,

R^1 represents halogen ~~or hydroxymethyl~~ and

R^2 represents –C_2H_5 optionally substituted in one or more places, the same way or differently, with hydroxy, imidazolyl
or represents –C_3H_7 or –C_4H_8 optionally substituted in one or more places, the same way or differently with the group –NH_2, –NH-(CO)-$CH(NH_2)$-C_2H_4-COOH, -NH-(CO)-phenyl, –NH-(CO)-CH_2-phenyl, -NH-(CO)-CH_2-$CH(CH_3)$-phenyl, –NH-(CO)-CH_2-O-phenyl, –NH-(CO)O-CH_2-phenyl, -NH-(CO)-$CH(NH_2)CH_2$-phenyl,



wherein phenyl can optionally be substituted in one or more places, the same or differently, with halogen, -CH_3 or –(CO)-$C(CH_2)(C_2H_5)$,
~~or represents C_3-alkinyl,~~

or a diastereomer, enantiomer or pharmaceutically acceptable salt thereof.

8. (Currently Amended) A compound ~~according to claim 7~~, which is N-[3-[[2-[[3-[[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,

1-[3-[[2-[[3-[[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2-oxo-3-pyrrolidinecarboxylic acid,

N-[3-[[5-bromo-4-[[3-[[(5-oxo-2-pyrrolidinyl)carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide,

Pyrrolidine-1-carboxylic acid [3-(5-bromo-4-{3-[2-(2,4-dichloro-phenyl)-acetylamino]-propylamino}-pyrimidin-2-ylamino)-phenyl]-amide,

Pyrrolidine-1-carboxylic acid [3-(5-bromo-4-{3-[2-(4-bromo-phenyl)-acetylamino]-propylamino}-pyrimidin-2-ylamino)-phenyl]-amide,

Pyrrolidine-1-carboxylic acid (3-{5-bromo-4-[3-(2-p-tolyl-acetylamino)-propylamino]-pyrimidin-2-ylamino}-phenyl)-amide,

Pyrrolidine-1-carboxylic acid [3-(5-bromo-4-{3-[2-(2,4-difluoro-phenyl)-acetylamino]-propylamino}-pyrimidin-2-ylamino)-phenyl]-amide,

Pyrrolidine-1-carboxylic acid {3-[5-bromo-4-(3-{2-[2,3-dichloro-4-(2-methylene-butyryl)-phenoxy]-acetylamino}-propylamino)-pyrimidin-2-ylamino]-phenyl}-amide,

Pyrrolidine-1-carboxylic acid [3-(5-bromo-4-{3-[3-(2,3-dichloro-phenyl)-butyrylamino]-propylamino}-pyrimidin-2-ylamino)-phenyl]-amide,

Pyrrolidine-1-carboxylic acid (3-{5-bromo-4-[3-(3-bromo-benzoylamino)-propylamino]-pyrimidin-2-ylamino}-phenyl)-amide,

N-(3-((4-((4-aminobutyl)amino)-5-bromo-2-pyrimidinyl)amino)phenyl)-1-pyrrolidinecarboxamide,

N-[3-[[2-[[3-[[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,

N-[3-[[(2*S*)-2-Amino-1-oxo-3-phenylpropyl]amino]-5-[[5-bromo-4-(prop-2-ynyloxy)pyrimidin-2-yl]amino]phenyl]pyrrolidine-1-carboxamide,

N-[3-[[(2*R*)-2-Amino-1-oxo-3-phenylpropyl]amino]-5-[[5-bromo-4-(prop-2-ynyloxy)pyrimidin-2-yl]amino]phenyl]pyrrolidine-1-carboxamide,

(α*R*)-α-Amino-*N*-[3-[[5-bromo-4-(prop-2-ynyloxy)pyrimidin-2-yl]amino]-5-

(hydroxymethyl)phenyl]benzenepropanamide,
2-[3-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-5-hydroxymethyl-phenylamino]-ethanol,
(2R)-Amino-N-[3-hydroxymethyl-5-(4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-phenyl-propionamide,
3-((2R)-Amino-3-phenyl-propionylamino)-5-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)- N-cyclopropyl-benzamide,
3-((2R)-Amino-3-phenyl-propionylamino)-5-(5-bromo-4-prop-2-ynyloxy-pyrimidin-2-ylamino)-N-isopropyl-benzamide,
Phenylmethyl [3-[[2-[[3-[[(ethylamino)carbonyl]amino]phenyl]amino]-5-(hydroxymethyl)pyrimidine-4-yl]amino]propyl]carbamate,
Pyrrolidine-1-carboxylic acid (3-{4-[3-((2R)-amino-3-phenyl-propionylamino)-propylamino]-5-bromo-pyrimidine-2-ylamino}-phenyl)-amide,
Pyrrolidine-1-carboxylic acid (3-{4-[3-((2S)-amino-3-phenyl-propionylamino)-propylamino]-5-bromo-pyrimidine-2-ylamino}-phenyl)-amide,
2-[3-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenylamino]-ethanol,
1-Amino-cyclopentancarbonylic acid[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-amide,
1-Amino-cyclohexancarbonylic acid-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-amide,
(2S)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-phenyl-propionamide,
(2R)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-phenyl-propionamide,
2-{[3-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenylamino]-methyl}-phenol,
(2R)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-(4-hydroxy-phenyl)-propionamide,
N-[3-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-(3,4-dihydroxy-phenyl)-propionamide,
N-[3-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-2-hydroxy-(2S)-phenyl-

acetamide,
N-[3-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-2-hydroxy-(2R)-phenyl-acetamide,
(2S)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-hydroxy-propionamide,
(2R)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidin-2-ylamino)-phenyl]-3-hydroxy-propionamide,
2-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-2-methyl-propionamide,
(2S)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-(4-hydroxy-phenyl)-propionamide,
(2S)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-p-tolyl-propionamide or
(2R)-Amino-N-[3-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenyl]-3-p-tolyl-propionamide,
or a pharmaceutically acceptable salt thereof.

9. (Currently Amended) A compound according to claim 6, in which

A or B in each case independently of one another represent ~~halogen,~~ hydrogen or the group $-SO_2-CH_3$, $-NO_2$, $-NH_2$, $-CF_3$, $-CH_2-NH-(CO)-NH_2$, -CH2-pyrrolidinyl, $-NH-(CO)-CH_3$, $-NH-(CO)-hexyl-NH_2$, -NH-(CO)-phenyl, -NH-(CO)-pyrrolidinyl, $--NH-(CO)-CH(NH_2)-CH_2$-phenyl, $NH-(CO)-OCH_3$, $-NH-(CO)-OCH(CH_3)_2$, $-NH-(CO)-OC_2H_4$-morpholino, -NH-(CO)-NH-cyclopropyl, -NH-(CO)-morpholino, $-NH-(CO)-NH-C_2H_4$-morpholino, -NH-(CO)-NH-hydroxycycloalkyl, hydantoinyl,
wherein pyrrolidinyl can optionally be substituted with hydroxy or the group $-NH_2$ and
wherein hydantoinyl can optionally be substituted with the group $-CH_3$ or -(CO)-thiazolidinonyl,

X represents the group –NH-,

R^1 represents halogen and

R^2 represents $-CH_2$-dihydroxyphenyl, $-C_2H_4$-imidazolyl, or $-C_3H_7$ optionally substituted in one or more places, the same way or differently, with



or a diastereomer, enantiomer or pharmaceutically acceptable salt thereof.

10. (Previously Presented) A compound, which is

4-((4-((2-(1H-imidazol-4-yl)ethyl)amino)-5-iodo-2-pyrimidinyl)amino)-benzenesulfonamide,

N-((3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)methyl)-urea,

1-((3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)methyl)-3-pyrrolidinol,

(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-carbamic acid methyl ester,

N2-(3-aminophenyl)-5-bromo-N4-(2-(1H-imidazol-4-yl)ethyl)-2,4-pyrimidinediamine,

N-(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-N'-cyclopropyl-urea,

N-(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-4-morpholinecarboxamide,

(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-carbamic acid 1-methylethyl ester,

N-(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-methanesulfonamide,

N2-(3-amino-5-(trifluoromethyl)phenyl)-5-bromo-N4-(2-(1H-imidazol-4-yl)ethyl)-2,4-pyrimidinediamine,

N-(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-N'-(2-(4-morpholinyl)ethyl)-urea,

N2-(3-amino-5-chlorophenyl)-5-bromo-N4-(2-(1H-imidazol-4-yl)ethyl)-2,4-pyrimidinediamine,

(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-carbamic acid 2-(4-morpholinyl)ethyl ester,

N-(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-N'-(4-hydroxycyclohexyl)-urea,

N-(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-acetamide,

N-(3-((5-bromo-4-((2-(1H-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-benzamide,

(4R)-N-[3-[[5-bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-pyrimidinyl]amino]propyl]-2-oxo-4-thiazolidinecarboxamide,

3-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-2,4-imidazolidinedione,

3-[3-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]phenyl]-1-methyl-2,4-imidazolidinedione,

1-[3-[[2-[[3-[[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2-oxo-3-pyrrolidinecarboxylic acid,

1-[3-[[2-[[3-[[(1-aminocyclohexyl)carbonyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-2-oxo-3-pyrrolidinecarboxylic acid,

N-[3-[[2-[[3-[[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-bromo-4-pyrimidinyl]amino]propyl]-5-oxo-2-pyrrolidinecarboxamide,

N-[3-[[2-[[3-[[(2R)-2-amino-1-oxo-3-phenylpropyl]amino]phenyl]amino]-5-chloro-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,

3-[3-[[5-bromo-4-[[(3,4-dihydroxyphenyl)methyl]amino]-2-pyrimidinyl]amino]phenyl]-2,4-imidazolidinedione,

3-[3-[[5-bromo-4-[[(3,4-dihydroxyphenyl)methyl]amino]-2-pyrimidinyl]amino]phenyl]-1-methyl-2,4-imidazolidinedione,

(4R)-N-[3-[[5-bromo-2-[[3-(2,5-dioxo-1-imidazolidinyl)phenyl]amino]-4-

pyrimidinyl]amino]propyl]-2-oxo-4-thiazolidinecarboxamide,
N-[3-[[5-bromo-2-[[3-(2,5-dioxo-1-imidazolidinyl)phenyl]amino]-4-pyrimidinyl]amino]propyl]-5-oxo-2-pyrrolidinecarboxamide,
N-[3-[[5-bromo-2-[[3-(2,5-dioxo-1-imidazolidinyl)phenyl]amino]-4-pyrimidinyl]amino]propyl]-2,2-dimethyl-propanediamide,
3-[3-[[5-bromo-4-[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]-2-pyrimidinyl]amino]phenyl]-2,4-imidazolidinedione,
(4R)-N-[3-[[5-bromo-2-[[3-(3-methyl-2,5-dioxo-1-imidazolidinyl)phenyl]amino]-4-pyrimidinyl]amino]propyl]-2-oxo-4-thiazolidinecarboxamide or
(4R)-N-[3-[[5-bromo-2-[[3-[2,5-dioxo-3-[[(4R)-2-oxo-4-thiazolidinyl]carbonyl]-1-imidazolidinyl]phenyl]amino]-4-pyrimidinyl]amino]propyl]-2-oxo-4-thiazolidinecarboxamide, or a pharmaceutically acceptable salt thereof.

11. (Previously Presented) A compound, which is
N-(3-((4-((3-(aminomethyl)phenyl)amino)-5-bromo-2-pyrimidinyl)amino)phenyl)-1-pyrrolidine-carboxamide,
4-[[5-bromo-4-[[2-(1H-imidazol-5-yl)ethyl]amino]-2-pyrimidinyl]amino]- 1-naphthaleneacetic acid,
5-[[5-bromo-4-[[2-(1H-imidazol-5-yl)ethyl]amino]-2-pyrimidinyl]amino]-1H-indole-2-carboxylic acid, ethyl ester,
5-bromo-N4-[2-(1H-imidazol-5-yl)ethyl]-N2-(2-methyl-6-quinolinyl)-2,4-pyrimidinediamine,
4-((5-bromo-4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)-benzamide,
4-((4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-5-iodo-2-pyrimidinyl)amino)-benzenesulfonamide,
3-((5-bromo-4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)-benzamide,
3-((5-bromo-4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)-benzenesulfonamide,
5-((5-bromo-4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)-1,3-dihydro-2H-benzimidazol-2-one,
3-((5-bromo-4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)- benzoic acid methyl ester,
3-amino-5-((5-bromo-4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)- benzoic acid

methyl ester,

N-((3-((5-bromo-4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)methyl)-methanesulfonamide,

4-((5-bromo-4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)- benzoic acid methyl ester,

3-((5-bromo-4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)-phenol,

5-((5-bromo-4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)-*1H*-isoindole-1,3(2H)-dione,

5-bromo-N^4-(2-(*1H*-imidazol-4-yl)ethyl)-N^2-(3-methylphenyl)-2,4-pyrimidinediamine,

N-(3-((5-bromo-4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)phenyl)-methanesulfonamide,

4-((4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-5-methyl-2-pyrimidinyl)amino)-benzenesulfonamide,

4-((4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-benzenesulfonamide,

4-((4-((3-aminopropyl)amino)-5-bromo-2-pyrimidinyl)amino)-benzenesulfonamide,

4-((5-bromo-4-((3-(*1H*-imidazol-1-yl)propyl)amino)-2-pyrimidinyl)amino)-benzenesulfonamide,

4-((5-bromo-4-((2-(1-pyrrolidinyl)ethyl)amino)-2-pyrimidinyl)amino)-benzenesulfonamide,

4-((4-((4-aminobutyl)amino)-5-bromo-2-pyrimidinyl)amino)-benzenesulfonamide,

4-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)-butanoic acid,

4-((4-((3-((aminocarbonyl)amino)propyl)amino)-5-bromo-2-pyrimidinyl)amino)-benzenesulfonamide,

4-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)-butanoic acid ethyl ester,

4-((5-bromo-4-((4-(methylamino)butyl)amino)-2-pyrimidinyl)amino)-benzenesulfonamide,

4-((5-bromo-4-((2-(*1H*-imidazol-1-yl)ethyl)amino)-2-pyrimidinyl)amino)-benzenesulfonamide,

4-((5-ethyl-4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)-benzenesulfonamide,

4-((4-((2-(*1H*-imidazol-4-yl)ethyl)amino)-2-pyrimidinyl)amino)-benzenesulfonamide,

4-((5-bromo-4-((2-(2-pyridinyl)ethyl)amino)-2-pyrimidinyl)amino)-benzenesulfonamide,

4-((5-bromo-4-((2-(*1H*-indol-3-yl)ethyl)amino)-2-pyrimidinyl)amino)-benzenesulfonamide,

2-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)-acetamide,

N-(2-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)ethyl)-acetamide,
3-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)-propanamide,
N-(4-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)butyl)-acetamide,
N-(3-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)propyl)-acetamide,
N-(3-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)propyl)-2-furancarboxamide,
N-(3-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)propyl)-*1H*-pyrrole-2-carboxamide,
4-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)-butanamide,
N-(3-((2-((4-(aminosulfonyl)phenyl)amino)-5-bromo-4-pyrimidinyl)amino)propyl)-2-thiophenecarboxamide,
4-((4-(4-(aminomethyl)-1-piperidinyl)-5-bromo-2-pyrimidinyl)amino)-benzenesulfonamide,
4-(5-bromo-4-prop-2-ynylamino-pyrimidin-2-ylamino)-phenyl]-N,N-dimethylaminosulfonylamin,
1-Methyl-1H-imidazol-4-sulfonic acid [4-(5-bromo-4-prop-2-ynylamino-pyrimidin-2-ylamino)-phenyl]-amid,
3-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-benzoic acid ethyl ester,
4-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-benzoic acid ethyl ester,
2-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-benzoic acid ethyl ester,
2-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-phenol,
4-(5-Bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-benzoic acid methyl ester,
3-(5-Nitro-4-prop-2-ynylamino-pyrimidine-2-ylamino)-phenol,
2-(5-Nitro-4-prop-2-ynylamino-pyrimidine-2-ylamino)-benzoic acid ethyl ester,
3-(5-Nitro-4-prop-2-ynylamino-pyrimidine-2-ylamino)-benzoic acid ethyl ester,
4-(5-Nitro-4-prop-2-ynylamino-pyrimidine-2-ylamino)-benzoic acid ethyl ester,
4-(5-Nitro-4-prop-2-ynylamino-pyrimidine-2-ylamino)-phenol,
Methyl 3-[[5-bromo-4-(prop-2-ynyloxy)pyrimidin-2-yl]amino]-5-[(2-hydroxyethyl)amino]benzoate,
Methyl 3-amino-5-[[5-bromo-4-(prop-2-ynyloxy)pyrimidin-2-yl]amino]benzoate or
3-[Bis-(2-hydroxy-ethyl)-amino]-5-(5-bromo-4-prop-2-ynyloxy-pyrimidine-2-ylamino)-benzoic

acid methyl ester,
or a pharmaceutically acceptable salt thereof.

12. (Previously Presented) A pharmaceutical composition comprising at least one compound according to claim 6 and a pharmaceutically acceptable carrier, diluent or excipient.

13-16. (Cancelled)

17. (Currently Amended) A method of treating ~~cancer~~ Kaposis sarcoma, Hodgkin's disease or leukemia comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition according to claim 12.

18. (Cancelled)

19. (Previously Presented) A method according to claim 17, wherein the patient treated is a mammal.

20. (Previously Presented) A method of claim 19, wherein the mammal is a human.

21-25. (Cancelled)

26. (Previously Presented) A pharmaceutical composition comprising at least one compound according to claim 11 and a pharmaceutically acceptable carrier, diluent or excipient.

27. (Currently Amended) A method of treating ~~cancer~~ Kaposis sarcoma, Hodgkin's disease or leukemia comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition according to claim 26.

28. (Cancelled)

29. (Previously Presented) A method of treating rheumatoid arthritis comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition according to claim 12.

30-31. (Cancelled)

32. (Previously Presented) A compound according to claim 6, wherein X represents an oxygen atom.

33. (Previously Presented) A compound according to claim 6, wherein X represents the group –NH-.

34. (Previously Presented) A compound according to claim 6, wherein A or B in each case independently of one another represent hydrogen or the group $-NO_2$, $-NH_2$, $-NR^3R^4$, $-N(C_{1-6}\text{-hydroxyalkyl})_2$, $-NH(CO)-R^5$, $-NHCOOR^6$, $-NR^7-(CO)-NR^8R^9$, $-NR^7-(CS)-NR^8R^9$, $-CO-NR^8R^9$, $-SO_2-CH_3$, 4-bromo-1-methyl-1*H*-pyrazolo-3yl or C_{1-6}-alkyl optionally substituted in one or more places, the same way or differently with cyano, hydroxy or the group $-NH_2$, $-NH-(CO)-R^5$, $-SO_2-NHR^3$, $-COOR^5$, $-CONR^8R^9$, $-O-(CO)-R^5$, $-O-(CO)-C_{1-6}$-alkyl-R^5.

35. (Cancelled)

36. (Currently Amended) A compound according to claim 6, wherein R^2 represents C_{1-6}-alkyl optionally substituted in one or more places, the same way or differently, with hydroxy, imidazolyl or the group –NH-(CO)O-CH_2-phenyl, -NH-(CO)H, -NH-(CO)-phenyl, -NH-(CO)-CH_2-O-phenyl, -NH-(CO)-CH_2-phenyl, -NH-(CO)-$CH(NH_2)CH_2$-phenyl, -NH-(CO)-CH_2-$CH(CH_3)$-phenyl, -NH-(CO)-

$CH(NH2)-(CH2)_2-COOH$,



wherein phenyl can optionally be substituted in one or more places, the same or differently with halogen, C_{1-6}-alkyl or $-(CO)-C(CH_2)-C_2H_5$, ~~or represents C_3-alkinyl~~.

37-38. (Cancelled)

39. (New) A compound according to claim 6, wherein

R^2 represents a straight chain or branched chain C_{1-6}-alkyl substituted in one or more places, the same way or differently, with hydroxy, imidazolyl or the group $-NH_2$, $-NH-(CO)O-CH_2$-phenyl, -NH-(CO)H, -NH-(CO)-phenyl, $-NH-(CO)-CH_2-O-$phenyl, $-NH-(CO)-CH_2$-phenyl, $-NH-(CO)-CH(NH_2)CH_2$-phenyl, $-NH-(CO)-CH_2-CH(CH_3)$-phenyl, -NH-(CO)-CH(NH2)-$(CH2)_2$-COOH,



wherein phenyl can optionally be substituted in one or more places, the same or differently with halogen, C_{1-6}-alkyl or $-(CO)-C(CH_2)-C_2H_5$.

40. (New) A pharmaceutical composition comprising at least one compound according to claim 39 and a pharmaceutically acceptable carrier, diluent or excipient.

41. (New) A method of treating Kaposis sarcoma, Hodgkin's disease or leukemia comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition according to claim 12.